PP
HAE icon

PDT Partners’s Haemonetics HAE Stock Holding History

PDT Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,512
Closed -$3.25M – 637
2025
Q2 		$3.25M Sell
43,512
-11,589
-21% -$767K 0.18% 193
2025
Q1 		$3.5M Buy
55,101
+44,933
+442% +$3.06M 0.25% 129
2024
Q4 		$794K Buy
+10,168
New +$817K 0.07% 385
2022
Q3 		– Sell
-5,703
Closed -$372K – 934
2022
Q2 		$372K Sell
5,703
-17,850
-76% -$1.06M 0.03% 687
2022
Q1 		$1.49M Buy
+23,553
New +$1.28M 0.13% 245
2020
Q3 		– Sell
-6,909
Closed -$619K – 780
2020
Q2 		$619K Buy
+6,909
New +$698K 0.04% 359
2013
Q4 		– Sell
-8,300
Closed -$331K – 841
2013
Q3 		$331K Sell
8,300
-16,853
-67% -$707K 0.01% 1210
2013
Q2 		$1.04M Buy
+25,153
New +$1.02M 0.03% 800

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's HAE Position: Q3 2025 in Review

PDT Partners sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 43,512 shares — an estimated $3.25M sold.

PDT Partners first reported a position in HAE in Q2 2013 and held it in 8 quarters. The position peaked at $3.5M in Q1 2025. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • PDT Partners reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
  • PDT Partners sold 43,512 Haemonetics shares in Q3 2025, an estimated $3.25M.
  • PDT Partners first reported a position in Haemonetics in Q2 2013 and held it in 8 quarters.
  • PDT Partners's Haemonetics position peaked at $3.5M in Q1 2025.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.